0 CHECKOUT

PRODUCT FILTERS

REGION

1,003
92
66
63
53

COUNTRY

60
13
11
8
6

CATEGORIES

  • 73
  • 124
  • 59
  • 54
  • 35
  • 33
  • 10
  • 10
  • 11
  • 14

PRICE

547
801
1,660
2,764

PUBLISHED

63
235
599
2,764

PRODUCT TYPE

2,657
87
7
6
2
2
2
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

2,764 Products

Liver Cancer Treatment Drugs Markets in China

China's demand for Liver Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high...

Published:  July 2015
Price:  From

Skin Cancer Treatment Drugs Markets in China

China's demand for Skin Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high...

Published:  July 2015
Price:  From

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023 Summary Multiple myeloma is a hematologic cancer of the white blood cell; more specifically, multiple myeloma is a cancer of the plasma...

Published:  July 2015
Price:  From

Biomarker Technology Platforms for Cancer Diagnoses and Therapies 2014

Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis....

Published:  July 2014
Price:  From

Companion Diagnostics in Personalized Medicine and Cancer Therapy

Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy This linkage could be important in the therapeutic...

Published:  June 2014
Price:  From

Global Breast Cancer Market 2014-2018

About Breast Cancer Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically,...

Published:  June 2014
Price:  From

Global Non-Melanoma Skin Cancer Market 2014-2018

About Non-melanoma Skin Cancer Non-melanoma skin cancer is one of the most common types of cancer in the world It develops in the upper layers of the skin, but not in melanocytes There are two types...

Published:  May 2014
Price:  From

Global Ovarian Cancer Market 2014-2018

About Ovarian Cancer and its therapy Ovarian cancer is a condition where a malignancy forms in the ovarian tissue and is caused by uncontrollable cell growth. It is one of the major gynaecological...

Published:  June 2014
Price:  From

Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the Treatment Paradigm of Prostate Cancer

XTANDI (Enzalutamide) – Does it have potential to compete against ARN-509 in earlier setting? Zytiga (Abiraterone Acetate) – Ongoing Combination trials creates potential beyond Patent Expiry In recent...

Published:  February 2014
Price:  From
Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the Treatment Paradigm of Prostate Cancer Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the Treatment Paradigm of Prostate Cancer - Product Thumbnail Image

Global Gynecological Cancers Market 2014-2018

The analysts forecast the Global Gynecological Cancers market to grow at a CAGR of 12.47 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase...

Published:  December 2013
Price:  From

Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A

The report (ToC) provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC)...

Published:  September 2013
Price:  From

Personalizing Cancer Drugs Trends

The report illustrates that understanding of cancer is shifting from a pathology-oriented perspective to a molecular perception Mechanisms responsible for driving cancer continue to emerge in diverse...

Published:  January 2014
Price:  From
Personalizing Cancer Drugs Trends Personalizing Cancer Drugs Trends - Product Thumbnail Image

Bladder Cancer: Disease and Pipeline Analysis

This report offers an in-depth market and pipeline analysis of the bladder cancer market. This unique therapeutic assessment provides an overview of the current and future bladder cancer clinical development...

Published:  March 2014
Price:  From

Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis

This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the glioblastoma multiforme (brain cancer) market not available elsewhere. This reports...

Published:  January 2014
Price:  From

Oncology Drug Funding 2013

A Comprehensive Intelligence Report on Oncology Drug Funding 2013 is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid...

Published:  September 2013
Price: 

Circulating Tumour Cells (CTCs) and Circulating Nucleic Acids (CNAs) in Research, Clinical & Diagnostics and in Drug R&D: An Integrated Market Study of Developments, Growth Areas and Opportunities

Market findings from this integrated study are based on 'real world' laboratory data, provided by end-users who investigate Circulating Tumour Cells (CTCs) and Circulating Nucleic Acids (CNAs) in the...

Published:  May 2014
Price:  From

Cancer Molecular Biomarkers 2014: A Global Market Study

Technological advances in molecular biology over the last decade are accelerating the development of new nucleic acid diagnostic tests These advances provide opportunities for faster, simpler and more...

Published:  March 2014
Price:  From

Cancer Molecular Diagnostics: Suppliers Market Report 2014

Cancer diagnostics is one of the most dynamic medical fields, reflecting efforts to translate new advances in cancer into improved tests and treatments Increasingly, researchers and clinicians pursue...

Published:  February 2014
Price:  From

Cancer Molecular Diagnostics: Market Developments, Growth Areas and Opportunities 2014

Cancer diagnostics is one of the most dynamic medical fields, reflecting efforts to translate new advances in cancer into improved tests and treatments Increasingly, researchers and clinicians pursue...

Published:  February 2014
Price:  From

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology,...

Published:  May 2013
Price:  From
Loading Indicator

Our Clients